UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 26, 2011
FURIEX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction
of incorporation)
| | |
| 001-34641 | | 27-1197863 |
| (Commission File Number) | | (IRS Employer ID Number) |
3900 Paramount Parkway, Suite 150, Morrisville, North Carolina 27560
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code(919) 456-7800
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On July 26, 2011, Furiex Pharmaceuticals, Inc. issued a press release announcing that Takeda Pharmaceutical Company Limited has resubmitted two new drug applications with the U.S. Food and Drug Administration, one for alogliptin and the other for a fixed-dose combination of alogliptin and pioglitazone. Under Furiex’s agreement with Takeda, these two resubmissions do not trigger a milestone payment to Furiex. If U.S. approval is granted, Furiex would be eligible to receive a $25 million milestone payment as well as potential royalties and sales-based milestones. Furiex presently receives royalty payments from Takeda for the sale of alogliptin, tradename Nesina®, in Japan. A copy of this press release is attached as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
| | |
Exhibit
No. | | Description |
| |
| 99.1 | | Press release issued July 26, 2011. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
| | |
| | FURIEX PHARMACEUTICALS, INC. |
| |
| Date: July 26, 2011 | | |
| | /s/ Marshall H. Woodworth |
| | Marshall H. Woodworth Chief Financial Officer |
